Anti-cancer magnetic guidance target drug slow release preparation.

, Introduction
Malignant tumors pose a serious threat to human health, with 10 million new cancer cases and 6 million deaths worldwide each year, accounting for 12% of the total annual deaths. The total number of cancer patients in China is about 4.5 million, the incidence rate is increasing at a rate of 2.5% per year, 1.8-2 million new patients per year, the mortality rate accounts for about 20% of the total death toll.
the current high dose of chemotherapy drugs on normal
tissues
has very strong toxic side effects and chemotherapy intermittent drug-resistant tumor cells appear, the increased risk of cancer metastasis is the main reason for the failure of chemotherapy. Therefore, it is important to seek high-efficiency, low-toxic targeted drugs or targeted slow release agents for malignant tumor lesions.
The anti-cancer magnetic guidance targeted drug slow release agent developed by this project consists of magnetic particles, skeleton material and anti-cancer drugs, which can be directed to the tumor lesions with the help of an external magnetic field induction, and make the anti-cancer drug slow in the lesions area. Release, concentrated role, with high local concentration of drugs, long direct contact with tumors, good targeting, low toxicity response, good tolerance, high safety, positive efficacy, convenient operation and so on, thus becoming an advanced targeted chemotherapy method in cancer treatment.
II, the principle of magnetically guided targeted preparations and composition of
anti-cancer magnetically directed targeted drug preparations on tumor cells by injecting the drug preparation into the body, induced by the external magnetic field, by targeting magnetic composite particles in the tumor area, anti-cancer drugs in the lesions area continued to release slowly, local concentration is high, thereby improving the anti-cancer drugs on cancer cells killing index.
The anti-cancer targeting agent can reduce the normal tissue distribution of the drug in the body, greatly reduce the toxic side effects of the drug, reduce the dose of anti-cancer drugs, solve the problem of poor repetition in the chemical treatment process, the toxic side reaction is obvious:
anti-cancer magnetically directed drug preparations Magnetic composite particles consisting of magnetic particles and skeleton materials are carriers in which anti-cancer drugs can target positioning and slow release, where magnetic particles are composed of iron oxide, and the skeleton materials are multi-selected inorganic or biodegradable medical molecules with good biosupability.
As a carrier of targeted drug preparations, magnetic compound particles should have good biocompaciability, high magnetic response sensitivity, long cycle time in the body, stable nature and so on, so as to ensure the targeted transport and slow release of anti-cancer drugs, while being able to circulate metabolism through their own bodies.
anticancer drugs need to choose different drugs according to the needs of malignant tumor treatment, currently used in clinical cancer treatment drugs such as yew alcohol, oxalipari, hydroxyl magpie, pyridoxine, 5-fluorouracil, hydrochloric acid aminocin, cisplatin, etc. can be combined with magnetic compound particles, forming a specific anti-cancer effect of targeted drug preparations.
, progress in the study of magnetically guided targeting agents
Magnetic-guided targeted drugs were first proposed by Widder and Senyei in the 1970s and applied to targeted treatment of tumors. In 1996, the first preclinical and clinical Phase I trials of magnetic drug-targeted cancer treatment were carried out in Germany, and during the treatment of 14 patients with advanced cancer, it was found that the resistance of magnetically directed targeted drugs was very good.
In 2002, FeRx developed a magnetically guided target vector, amycin, approved by the U.S. Food and Drug Administration (FDA), to conduct phase I/II. clinical trials for magnetically guided targeted treatment of hepatocellular carcinoma, and the results indicate that this new technology has great potential in the treatment of liver cancer. China has also carried out research on the targeted treatment of cancers such as liver cancer by magnetic albumin composite particles with amycin as an anti-cancer drug, and has also obtained good experimental results.
But at present, the world's anti-cancer magnetic guidance targeted drugs are in the laboratory research stage, has not been approved by the FDA or the State Food and Drug Administration (SFDA) for sale of anti-cancer magnetically directed drugs, so the development of anti-cancer magnetically directed drugs is still a worldwide hot spot for targeted drug development, included in the "12th Five-Year Plan" period "863" plan and major new drug creation and other major research plans.
.